If you have registered for today's event, please click the button below to join the webcast. You can join as early as 12:00 P.M. ET.
Event registration is now closed. For assistance with registration, please contact marketing@globeandmail.com.
Canadian researchers are in the process of exploring new approaches to diagnosing, treating and managing illnesses such as cancer, heart disease and neurological disorders with nuclear medicine. What innovations and discoveries hold the most promise for patient care and outcomes? This webcast will explore the breakthroughs, advancements and policy issues shaping nuclear medicine today, along with plans and actions to ensure Canada continues to play a leadership role.
If you have registered for today's event, please click the button below to join the webcast. You can join as early as 12:00 P.M. ET.
Event registration is now closed. For assistance with registration, please contact marketing@globeandmail.com.
Maia Ingram
Program Manager, Isotopes and Business Development, Bruce Power
Kathryn Hayashi
President & CEO, TRIUMF Innovations
Karin Stephenson
Director, Research Platforms, McMaster University
Dr. Sten Myrehaug
Radiation Oncologist, Clinician Investigator, Odette Cancer Centre, Sunnybrook Health Sciences Centre
André Picard
Health Reporter and Columnist, The Globe and Mail
Canadian researchers are in the process of exploring new approaches to diagnosing, treating and managing illnesses such as cancer, heart disease and neurological disorders with nuclear medicine. What innovations and discoveries hold the most promise for patient care and outcomes? This panel will cover the breakthroughs, advancements and policy issues shaping nuclear medicine today, along with plans and actions to ensure Canada continues to play a leadership role.
The CNIC is a coalition of science, health-care and nuclear-sector organizations to ensure Canada remains a world leader in the production of life-saving isotopes by bringing awareness and supporting long-term policies at the domestic and international level that will save countless lives and support health-care innovation for decades to come. To learn more about the CNIC visit www.CanadianIsotopes.ca and follow us on, Facebook, Twitter, and LinkedIn.
Bruce Power is an electricity company based in Bruce County, Ontario. We are powered by our people. Our 4,200 employees are the foundation of our accomplishments and are proud of the role they play in safely delivering clean, reliable, low-cost nuclear power to families and businesses across the province and life-saving medical isotopes around the world. Bruce Power has worked hard to build strong roots in Ontario and is committed to protecting the environment and supporting the communities in which we live. Formed in 2001, Bruce Power is a Canadian-owned partnership of TC Energy, OMERS, the Power Workers’ Union and The Society of United Professionals. Learn more at www.brucepower.com and follow us on Facebook, Twitter, LinkedIn, Instagram and YouTube.
André Picard is a health reporter and columnist for The Globe and Mail, where he has been a staff writer since 1987. He is also the author of five bestselling books.
André is an eight-time nominee for the National Newspaper Awards, Canada’s top journalism prize, and past winner of the prestigious Michener Award for Meritorious Public Service Journalism.
He was named Canada’s first “Public Health Hero” by the Canadian Public Health Association, as a “Champion of Mental Health” by the Canadian Alliance on Mental Illness and Mental Health, and received the Queen Elizabeth II Diamond Jubilee Medal for his dedication to improving healthcare.
André is a graduate of the University of Ottawa and Carleton University, and has received honorary doctorates from six universities, including UBC and the University of Toronto.
Ms. Kathryn Hayashi is President and CEO of TRIUMF Innovations, the business interface and commercialization arm, connecting TRIUMF, Canada's particle accelerator centre, to the private sector via industry partnerships, licensing, and company creation.
Ms. Hayashi is a Chartered Professional Accountant with more than 25 years of operational and strategic planning, finance and governance experience in not-for-profit organizations, public and private companies, start-ups, and commercialization accelerators/incubators.
Prior to TRIUMF Innovations, she was the Founding Chief Financial Officer of The Centre for Drug Research and Development, Canada’s national drug development and commercialization engine. In addition to her work establishing CDRD as a leader in pre-clinical translational research and commercialization, Ms. Hayashi presides as a Director and Audit Committee Chair
for Michael Smith Health Research BC, Center for Commercialization and Cancer Immunotherapy at the Hôpital Maisonneuve-Rosemont, as well as the Discovery Parks technology incubator, and has served on the boards of several spinoff companies.
Maia Ingram is a Program Manager for Isotopes & Business Development at Bruce Power. In this role, she focuses on new business opportunities outside of the traditional business of electricity generation and is currently focused on the development of medical isotope production using the nuclear reactors. Providing consulting services for almost 15 years in energy, engineering, and construction, she likes to apply her knowledge to improve business development practices, leverage economic trends, foster strong customer relationships, and develop sustainable growth strategies. Maia holds a Bachelor of Science in Economics from the University of Victoria, an MBA from Queen's Smith School of Business, and her Project Management Professional designation.
As the University’s first Director of Research Platforms Support, Karin leads the development, implementation, and operational management of McMaster’s core research platforms. Her experience in medical isotopes and radiopharmaceutical development spans nearly two decades and includes leadership roles in McMaster’s Nuclear Operations and Facilities, where she identified R&D opportunities and significantly grew McMaster’s nuclear commercial operations; and at CPDC, where she led the research and discovery of new radiochemistry and radiopharmaceuticals.
Karin holds a PhD in Chemistry from McMaster University and completed post-doctoral fellowships at the University of Pennsylvania and the Centre for Addiction and Mental Health/University of Toronto. She has numerous patents, papers published and has been awarded for her research.
Sten Myrehaug received his Doctor of Medicine with Special Training in Research from the University of Alberta, and completed his post-graduate training in Radiation Oncology at the University of Toronto. He subsequently did a clinical research fellow at the Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, with a focus on advanced imaging of central nervous system malignancies. He has been an active staff at the Odette Cancer Centre since 2015, with a clinical focus on CNS, GI and neuroendocrine malignancies. He has special interest in stereotactic radiosurgery in these clinical sites, and has an active research program in advanced MRI for primary brain tumors.
